Free Trial
NASDAQ:APVO

Aptevo Therapeutics 5/8/2024 Earnings Report

Aptevo Therapeutics logo
$3.00 -0.01 (-0.33%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$2.98 -0.02 (-0.67%)
As of 07/11/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptevo Therapeutics EPS Results

Actual EPS
-$272,431.00
Consensus EPS
-$386,058.00
Beat/Miss
Beat by +$113,627.00
One Year Ago EPS
N/A

Aptevo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aptevo Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Aptevo Therapeutics' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules.

Conference Call Resources

Aptevo Therapeutics Earnings Headlines

APVO Aptevo Therapeutics Inc. - Seeking Alpha
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Aptevo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptevo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptevo Therapeutics and other key companies, straight to your email.

About Aptevo Therapeutics

Aptevo Therapeutics (NASDAQ:APVO), Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative immunotherapies for cancer and other serious diseases. Founded as a spin-off from Emergent BioSolutions in 2010 and based in Seattle, Washington, Aptevo leverages two proprietary protein-engineering platforms—ADAPTIR and TriTAC—to create next-generation modular therapeutic proteins. The ADAPTIR platform enables the rational design of bispecific and multispecific molecules tailored to engage immune cells and disease targets, while the TriTAC platform extends this approach by recruiting and activating T cells to attack tumor cells with high specificity.

Aptevo’s pipeline includes multiple product candidates designed to address both solid tumors and hematologic malignancies. Among these, lead programs target well-validated cancer antigens such as programmed cell death protein 1 (PD-1), CD20 and B-cell maturation antigen (BCMA). Each molecule is engineered to optimize pharmacokinetics, minimize off-target effects and enhance immune activation. In addition to oncology, the company is exploring applications in autoimmune and inflammatory disorders by leveraging its platform’s flexibility to fine-tune immune responses.

The company conducts global clinical trials across North America, Europe and Asia in collaboration with academic institutions and strategic partners. Aptevo maintains manufacturing and research facilities in the Seattle region, supported by contract development and manufacturing organizations (CDMOs) to ensure scalable production of its complex biologics. Regulatory interactions and clinical data reviews have positioned several candidates for potential partnerships and out-licensing discussions, reflecting Aptevo’s strategy of combining internal development with external collaboration to advance its programs efficiently.

Leadership at Aptevo is headed by President and Chief Executive Officer David Hallal, Ph.D., a biotech industry veteran with extensive experience in antibody engineering and clinical development. The executive team includes seasoned professionals in regulatory affairs, translational medicine and commercial planning. Guided by a board of directors comprising experts in oncology, immunology and corporate governance, Aptevo aims to translate its proprietary platforms into transformative therapies that address unmet medical needs and improve patient outcomes worldwide.

View Aptevo Therapeutics Profile

More Earnings Resources from MarketBeat